Barchart Research What to Expect from BHC Earnings BHC Generated April 28, 2026 Current Price $5.67 EPS Estimate $$0.81 Consensus Rating Hold Average Move 7.25% Bausch Health: The Xifaxan Clock Ticks Louder...
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels
LAVAL, QC , March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch...
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026
LAVAL, QC , Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics,...
The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline
Shares of Bausch Health Companies Inc. (BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate...
LAVAL, QC and CUPERTINO, Calif. , July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation...